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ing author. Tel.: 01792 5
ess: m.j.lewis@swanseaSummary Patients with asthma have exaggerated bronchoconstriction of their
airways in response to certain indirect (e.g. cold air, allergens, dust, exercise) or
direct (e.g. inhaled methacholine) stimuli. This ‘hyper-reactivity’ usually co-exists
with airway inflammation, although the pathophysiological mechanisms underlying
these changes are not fully understood. It is likely that this hyper-reactivity is
associated with abnormal autonomic nervous system (ANS) control. In particular, the
parasympathetic (vagal) component of the ANS appears to be implicated in the
pathogenesis of asthma. In addition, several studies have suggested the existence of
differential alteration in ANS function following exercise in asthmatics compared
with non-asthmatic individuals.
Several early studies suggested that the altered autonomic control of airway
calibre in asthma might be reflected by a parallel change in heart rate. Cardiac vagal
reactivity does indeed appear to be increased in asthma, as demonstrated by the
cardiac response to various autonomic functions tests. However, other studies have
reported a lack of association between bronchial and cardiac vagal tone, and this is
in accord with the concept of system-independent ANS control.
This review provides a discussion of cardiovascular–autonomic changes associated
with either the pathophysiology of asthma per se or with asthma pharmacotherapy
treatment. Previous investigations are summarised suggesting an apparent associa-
tion between altered autonomic–cardiovascular control and bronchial asthma. The
full extent of autonomic dysfunction, and its clinical implications, has yet to be fully
determined and should be the subject of future investigation.
& 2006 Elsevier Ltd. All rights reserved.Contents
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The term ‘asthma’ encompasses several distinct
disease phenotypes leading to differences in
diagnostic classification. The most widely accepted
definition is ‘a chronic inflammatory disorder of the
airwaysy usually associated with widespread but
variable airflow obstruction and an increase in
airway response to a variety of stimuli’.1 About 5.2
million people in the UK have asthma, causing
about 69,000 hospital admissions and 1400 deaths
in 2003/2004 with an estimated direct cost to the
National Health Service of £889 million.2 Asthma
also causes a lot of morbidity with over 70% of
sufferers experiencing regular restrictions in their
activity.2
Patients with asthma undergo episodes of ex-
aggerated bronchoconstriction in response to a
wide variety of exogenous and endogenous stimuli
(for example cold air, organic/inorganic allergens
including dust or exercise). Recent guidelines have
emphasised the roles of certain allergens and their
avoidance in managing asthma.3 This ‘hyper-reac-
tivity’ is generally co-existent with (biopsy proven)
airway inflammation and is associated with altered
sensory neuronal activity. The pathophysiological
mechanism underlying these changes is not fully
understood but it is often triggered by allergens
and is typified by the presence of eosinophils and
TH2-type immune processes. It is likely that this
mechanism is associated with the abnormal auto-
nomic nervous system (ANS) control observed in
asthmatic subjects.4 In particular, the parasympa-
thetic component of the ANS appears to be
implicated in the pathogenesis of asthma. The
parasympathetic nervous system is involved in the
bronchoconstriction that occurs during physical
exercise in both asthmatic and non-asthmatic
subjects,5 the bronchoconstriction response to
altered airway temperature and/or airway surface
osmolarity.6 In addition, several studies have
suggested the existence of differential autonomicfunction following exercise in asthmatics compared
with normal controls.7–10
Cardiac vagal activity also appears to be in-
creased in asthma, as demonstrated by the ex-
aggerated cardiac response (bradycardia) to
anticholinergic drugs, methacholine and antigen
challenge seen in asthmatic subjects.11,12 It has
therefore been suggested that there might be an
intrinsic relationship between cardiac and bron-
chial autonomic control, and that this relationship
might be altered in asthmatic individuals.13 How-
ever, vagal regulation of resting bronchomotor tone
depends on reflexes initiated in irritant airway
receptors,14,15 whilst vagal activity to the heart
occurs in response to arterial baroreceptors.16,17
This apparent independence of vagal control
suggests that bronchial and cardiac vagal activities
would be unrelated. In accordance with this
concept of system-independent ANS control, some
authors have reported a lack of association be-
tween changes in ANS control in the cardiac and
respiratory systems. For example, Horva´th et al.18
found no correlation between bronchial and cardiac
vagal tone (assessed using airway resistance and
heart beat period) in non-atopic healthy adults.
However, there is also a considerable body of
evidence suggesting that numerous cardiovascular
parameters are altered as a result of either
pathophysiological changes or the administration
of therapeutic medication in asthma.Mechanisms of control in the respiratory
and cardiac systems
Mechanisms of airway control
Pre-ganglionic parasympathetic nerve fibres pro-
ject to the airways via the vagus nerves.
They form cholinergic synapses with post-gang-
lionic neurons via airway parasympathetic ganglia.
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M.J. Lewis et al.1690Airway parasympathetic ganglia are mainly asso-
ciated with the larger airways but the subsequent
post-ganglionic fibres innervate structures through-
out the airway tree.19 Post-ganglionic parasympa-
thetic cholinergic and non-adrenergic non-cholinergic
(NANC) fibres innervate (i) airway smooth muscle,
providing the dominant control of smooth muscle
tone and thus airway calibre, and (ii) airway glands
and microvasculature in the respiratory tract. There
is no sympathetic innervation of airway smooth
muscle, although the airway vasculature does receive
sympathetic innervation. Instead, relaxant innerva-
tion of the human airways is provided by the NANC
component of the parasympathetic nervous system,Spinal
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Influences on the cardiovascular system in asthma 1691activity of the sinoatrial (SA) node. The temporal
investigation of HR regulation is commonly referred
to as HR variability (HRV) analysis, and this can be
achieved using a variety of data processing techni-
ques in both the time and frequency domains. The
sympathetic and parasympathetic components of
the ANS influence the HRV signal in a frequency-
dependant way: the high-frequency (HF) compo-
nent of the HRV signal (in the range 0.15–0.4 Hz)
are mediated via the parasympathetic system; (ii)
the low-frequency (LF) component (in the range
0.04–0.15 Hz) are mediated via both sympathetic
and parasympathetic systems.20–22 Of particular
interest in the present context, the HF component
is associated with HR modulation caused by
respiratory influence.23 These respiratory effects
are often described as ‘respiratory sinus arrhyth-
mia’ (RSA), the phenomenon of HR modulation that
occurs at the frequency of respiration. RSA is the
pattern of rhythmic variation of HR that occurs at
the frequency of respiration, and which is mediated
by the vagus nerve.24 The HF component of HRV is
also influenced by respiratory tidal volume, and this
effect may be separately distinguished as ‘breath
amplitude sinus arrhythmia’ (BASA).23Relative influence of NO in the bronchial and
cardiac systems
Excitatory NANC mechanisms (e.g. the neuropep-
tides neurokinin A, calcitonin gene-related peptide,
substance P, bradykinin, tachykinin, neuropeptide Y)
cause bronchoconstriction, microvascular leakage
and mucous hyper-secretion.25–27 Inhibitory NANC
mechanisms (NO and VIP) constitute the only known
neural bronchodilator pathway in human airways.
Both NO and VIP inhibit the release of acetylcholine
and relax human isolated bronchial tissue.25,28 In
contrast, NO enhances both the activity of central
vagal motorneurons29 and the cardiac response to
vagal stimulation.30,31 Several authors have also
suggested that NO is a sympatholytic agent in
animals, i.e. it reduces the activity of sympathoex-
citatory brain stem nuclei and central sympathetic
outflow32–34 and it attenuates the cardiac response
to sympathetic stimulation.31 Chowdhary et al.35
provided the first evidence of a substantive effect of
NO on human cardiac autonomic control. In that
study systemic inhibition of NO synthase using NG-
monomethyl-L-arginine (L-NMMA) was associated
with an increase in HR and a reduction in HRV. The
opposite effect was noted following infusion of the
NO donor sodium nitroprusside. These authors
concluded that NO has a tonic excitatory influence
on baroreflex-mediated cardiac vagal activity.Review of the literature
Methodology
Studies that investigated cardiovascular physiolo-
gical changes resulting from the pathophysiology of
asthma or the pharmacological effects of asthma
medication were sought from the published litera-
ture. Studies included in the review fulfilled the
following criteria: either (i) they described a
qualitative or quantitative investigation of cardio-
vascular physiological parameters in asthmatic
and/or atopic individuals, or (ii) they described
the effects of pharmaceutical agents used in the
management of asthma, in individuals with or
without asthma or atopy. Studies that involved
either adults or children were included. Articles
that only described respiratory or other systemic
changes in asthma or asthma therapy, but did not
otherwise satisfy the admission criteria, were
excluded from the review.
A systematic search of the literature was
performed using a selection of electronic literature
databases (PubMed, BIDS, CINAHL). The keywords
shown in Table 1 were used to filter relevant
publications, using keyword combinations con-
structed as ‘Levels 1 and 2’. Citation tracking was
performed from the articles obtained via the
databases, yielding a second source of references.
A total of 23 studies satisfied the eligibility criteria
for the review. Table 2 provides a synopsis of the
main characteristics of each of the relevant
studies.
Results
The role of the autonomic nervous system in
asthma
Asthma is associated with abnormal ANS function
(dysautonomia) in adults.4 This is exhibited as: (i) a
marked bronchial hyper-sensitivity to cholinergic
and NANC constrictors, and (ii) a decreased
sensitivity to adrenergic and NANC dilators.36,37
Cholinergic responsiveness. The bronchi are toni-
cally constricted at rest38 owing to inspiratory
reflex cholinergic activity.14,39 There is evidence
that tonic parasympathetic (vagal) activity is
largely responsible for the maintenance of this
resting airway calibre.10,40,41 The parasympathetic
nervous system also has a role in reflex broncho-
constriction42 and it is generally accepted that this
effect is exaggerated in asthmatics, causing a
hyper-responsiveness to cold air, rapid breathing,
sulphur dioxide, citric acid and histamine. Asth-
matic airways are hyper-reactive and respond to
ARTICLE IN PRESS
Table 1 Combinations of terms used to search
the electronic literature databases (MeSH indicates
that the term is a medical subject heading).
Level 1 Level 2
Asthma (MeSH) or
asthmatic
1. Autonomic or autonomic
nervous system (MeSH) or
ANS
2. Sympathetic nervous
system (MeSH)
3. Parasympathetic nervous
system (MeSH)
4. Heart (MeSH) or cardiac or
cardiovascular system
(MeSH)
5. Blood pressure (MeSH)
6. Pressoreceptors (MeSH) or
baroreceptor or BRS
7. Heart rate (MeSH) or heart
rate variability or HRV
8. Autonomic pathways
(MeSH) or nerves or
nervous system (MeSH)
9. (Cholinergic or muscarinic
or adrenergic) and (agents
or agonists or antagonists)
(MeSH)
10. Sympathomimetics (MeSH)
or sympathomimetic or
anticholinergic
11. Adrenal cortex hormones
(MeSH) or corticosteroid or
glucocorticosteroid
Hypersensitivity
(MeSH) or atopy or
atopic
M.J. Lewis et al.1692doses of inhaled methacholine or carbachol (choli-
nergic agonists) that do not affect normal sub-
jects.4 Specific antigen challenge also causes
immediate bronchoconstriction followed by hyper-
reactivity.43–45 Animal experiments have abolished
both bronchoconstriction and hyper-reactivity by
vagotomy or vagal blockade.46 Cholinergic (para-
sympathetic) hyper-sensitivity can occur in differ-
ent body systems, being exhibited as exaggerations
in smooth muscle tone, pulmonary blood flow,
endothelial permeability, airway secretions47 or
sweating (eccrine gland response).48 Enhanced
cholinergic airway responsiveness has even been
suggested as a contributing factor to the develop-
ment of bronchial asthma.13,49 The abnormally
increased airway tone and hyper-reactivity in
asthma49,50 might be caused by either (i) an
increased release of acetylcholine from nerves, or
(ii) increased sensitivity of the post-junctional
muscarinic receptors. Anticholinergic drugs such
as atropine and ipratropium diminish both theincreased constrictive tone and the airway hyper-
reactivity in asthmatic individuals,36,51,52 thereby
confirming the cholinergic nature of the hyper-
sensitivity. Ipratopium bromide has been used in
the management of acute asthma.3
Adrenergic responsiveness. In addition to exag-
gerated cholinergic reactivity, changes in adrener-
gic activity have also been documented in
asthmatic subjects. Kaliner et al.4 compared the
response of allergic asthmatic, allergic rhinitic,
allergen-sensitive and normal control subjects to
alpha (a) adrenergic, beta (b) adrenergic and
cholinergic stimuli. These authors observed that
asthmatic subjects had hyper-reactive a-adrenergic
responsiveness and hypo-reactive b-adrenergic re-
sponsiveness. Furthermore, there are four types of
b receptor53; of these both b1 and b2 adrenoceptors
are found in the lung but b2 is the most important
and most widely expressed, as demonstrated by
autoradiographic imaging.54 Indeed one of the
cornerstones of contemporary asthma therapy is
the b2-adrenoceptor agonist (e.g. salbutamol), the
function of which is to stimulate b2-adrenergic
receptors in the lung and thus produce bronchodi-
lation. b1 receptors in the lung are confined to
glands and alveoli and therefore b1-adrenoceptor
agonists do not relax airway smooth muscle.
NANC responsiveness. Although the evidence for
clinically significant NANC dysfunction in asthma is
not yet conclusive, there is reason to believe that
inhibitory NANC mechanisms might be reduced and
excitatory NANC mechanisms might be increased in
asthma.25,55 Several possible mechanisms have
been proposed in support of an altered NANC
responsiveness in asthma, and this dysfunction
might be expected to exaggerate bronchoconstric-
tion in asthmatic individuals.
NO (one of the inhibitory NANC mediators) is
widely distributed in the body, functioning as a
messenger in a variety of biological processes. NO is
broken down by oxygen free radicals associated
with inflammatory cells,56 thereby degrading its
bronchodilatory effect. There is evidence that
exhaled NO levels correlate with markers of asthma
disease control such as eosinophil concentration
determined from bronchial biopsy and bronchial
lavage.57 Notably, the distinction between atopic,
asthmatic and atopic-asthmatic individuals seems
to be important in this regard. It is also possible
that dysregulation of NO production alters the
control of blood flow in the lungs and airways, and
thus contributes to the pathogenesis of asthma.58
Similarly, the enzymatic degradation of VIP might
be enhanced in severe asthma, for example as a
result of the release of tryptase from mast cells.25
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M.J. Lewis et al.1696More recently there has been discussion of the
link between exercise-induced bronchoconstriction
and NO in patients with asthma. Kanazawa et al.59
found that episodes of bronchoconstriction in
susceptible patients were associated with in-
creased sputum concentrations of NO derivatives,
and excess NO production was associated with
prolonged airway narrowing. Moreover, inhibition
of NO synthesis reduces airway constriction follow-
ing exercise.60 These results suggest that NO has an
important role in the pathogenesis of exercise-
induced asthma.
Interaction between the cardiac and respiratory
systems in asthma
Heart rate and its variability. Kallenbach et al.13
suggested that altered autonomic control of airway
calibre in asthma might be reflected by a parallel
change in HR. Several authors later reported
tendencies towards higher resting HRs in asthmatic
subjects compared with non-asthmatic con-
trols.61,62 Garrard et al.62 found that resting
HR was significantly higher in acute asthmatics
compared with both non-asthmatics and asympto-
matic asthmatics. The observed increase in HR
suggested an increased sympathetic tone and
higher levels of circulating catecholamines in the
asthmatic individuals.63 Shah et al.61 tested sym-
pathetic response by observing the systemic (HR
and blood pressure (BP)) responses to a sustained
hand grip test and to a change of posture. These
authors found that there was a tendency for
asthmatic subjects to display an exaggerated
fall in systolic BP on standing and an exaggerated
rise in diastolic BP in response to a sustained hand
grip test.
Tokuyama et al.64 observed that both asthma and
allergy are associated with increased parasympa-
thetic activity and that asthma causes increased
total HRV. Later, Shah et al.61 assessed basal
parasympathetic tone via the rise in HR induced
by postural change and atropine administration
tests. These authors observed a tendency towards a
greater HR response to atropine in asthmatic
subjects compared with non-asthmatic controls.
Although basal parasympathetic (vagal) tone was
not found to differ significantly between these two
groups, cardiac vagal reactivity was significantly
greater in asthma. In fact the authors associated
the severity of asthma with the magnitude of vagal
reactivity. This was demonstrated by the signifi-
cantly greater cardiac responses to deep breathing
(RSA), Valsalva manoeuvre and carotid massage
in asthmatic subjects compared with controls.
Vagal reactivity results were similar when subjects
were analysed in atopic asthmatic and non-atopicasthmatic subgroups, but vagal tone was signifi-
cantly greater in the atopic group.
Circadian patterns of autonomic control. The
nocturnal worsening of asthma manifests as a
reduction in lung function, an increase in bronchial
hyper-reactivity and increased wheezing. These
changes have been related to diurnal changes in
both hormone concentration and ANS control.65
Several authors have also documented a circadian
pattern in the components of HRV, the LF component
having minimal power and the HF component having
maximal power during the nocturnal period.66–68
Morrison et al.69 investigated the effects of vagal
blockade with atropine on both nocturnal peak
expiratory flow rate (PEFR) and HR in asthmatic
subjects. Atropine administration during the day and
night (at 4 am and 4 pm) caused significant
bronchodilatation (PEFR increased from 260 to
390 lmin1 at 4 am and from 400 to 440 lmin1 at
4 pm). There was a significant concomitant increase
in HR from 60 to 121 beatsmin1 at 4 am and from
76 to 122beatsmin1 at 4 pm. The authors noted
that nocturnal asthma effects were almost totally
reversed by atropine, implying that vagal mechan-
isms are fundamental in its pathophysiology. Morri-
son and Pearson70 subsequently demonstrated a
circadian variation in vagal activity on bronchomotor
tone and HR, with higher vagal activity during the
night (4 pm) compared with during the day (4 am).
It has since been confirmed that cardiac vagal tone
is enhanced at a time corresponding to the
usual sleep period, with an acrophase between 4
am and 5 am.71 This corresponds closely with the
documented period of maximal bronchoconstriction
in nocturnal asthma, suggesting that there might be
a common vagal influence in the bronchial and
cardiac systems.
Impact of pharmacological agents on the
cardiovascular system in asthma
The aims of pharmacological management are the
control of symptoms, prevention of exacerbations
and the achievement of best possible pulmonary
function with minimal side effects.3 Short-acting
beta-agonists (SABAs) are prescribed at all levels
of severity of asthma as well as in high dose
inhaled, nebulised and intravenous routes during
acute attacks. In chronic management, about 30%
of asthmatics are prescribed SABAs alone, as
required (Step 1, BTS Guidelines); about 12% of
asthmatics are prescribed a long-acting beta-
agonist (LABA) as add on therapy when moderate
doses of inhaled corticosteroids (200–800mcg
beclomethasone equivalent) do not control their
disease (Step 3). A further 6% of asthmatics are
prescribed LABAs in conjunction with regular
ARTICLE IN PRESS
Influences on the cardiovascular system in asthma 1697aminophylline/leukotriene antagonists (Step 4) or
in addition to regular oral steroids (Step 5).3
Influence of b-adrenoceptor agonists and antago-
nists in healthy individuals. b-adrenergic stimula-
tion of the human respiratory tract produces
several responses of benefit to the asthmatic
patient: bronchodilation,72 increased water and
chloride flux (which might reduce the viscosity
of tracheobronchial secretions),73 and impairment
of the immunological release of the mediators of
allergy.74 However, several relatively mild adverse
effects of b2-adrenoceptor agonists have also been
reported, including tremor, palpitations and head-
ache after taking salbutamol.75 The main adverse
effects of oral and inhaled b2 agonists relate to
their systemic activity following drug absorption
into the blood, with subsequent cardiovascular,
metabolic and neuronal changes.76
Specific potential adverse cardiovascular effects
of b2-adrenoceptor agonists include: circulatory
disturbances via (i) hypokalemia (including electro-
cardiographic anomalies such as a reduction in
amplitude of the T-wave); (ii) prolongation of the
cardiac depolarisation–repolarisation (QT) interval
and sinus tachycardia77; (iii) interference with
cardiovascular and respiratory autonomic con-
trol.78 The cardiovascular actions of b adrenergic
agonists result from (i) direct chronotropic and
inotropic myocardial influences, and (ii) indirect
rate effects resulting from baroreceptor reflex
responses to b2-mediated dilation of peripheral
arterioles.79–81 The chronotropic and inotropic
effects are mediated via both b1 and b2 receptors
of the heart.82–84 However, it is more likely
that contractile changes are b1 effects, whilst
HR changes can be either b2 or both b1- and
b2-mediated.
85 These potential side effects are
clinically relevant with many patients unable to
tolerate SABAs and especially LABAs because of
palpitations (KEL–pers. comm.).
Most investigations using HRV analysis suggest a
shift of the ANS’s sympathovagal balance towards
sympathetic dominance following administration of
b2 agonist medication.
78,86,87 Relative sympathetic
hyper-activity in the cardiovascular system is in
itself associated with increased mortality and
morbidity and with an increased risk of sudden
coronary death.88,89 Consequently it is possible that
these drugs might be implicated in the pathogen-
esis of a number of cardiovascular risk factors,
including insulin resistance, hyper-tension and
cardiovascular hyper-trophy,90 and in the evolution
of conditions such as coronary artery disease (CAD)
and sudden coronary death. Salpeter et al.91 have
performed a meta analysis of studies evaluating the
cardiovascular safety of b2 agonists in patients withobstructive airway disease, concluding that their
use increases the risk for adverse cardiovascular
events. There is also some evidence that the
systemic effects of inhaled b2 agonists might be
greater in healthy individuals compared with
asthmatic patients.92
It is instructive here to also briefly consider the
cardiovascular effects of b-adrenoceptor antago-
nists, and specifically their possible effects in
asthmatic individuals. The majority of studies
into the effects on cardiac autonomic control of
b-adrenoceptor antagonism in cardiovascular dis-
ease states have involved b1 receptor antagonists.
The results of these studies suggest a shift in
autonomic balance towards enhanced parasympa-
thetic and reduced sympathetic activity, generally
acknowledged to be a ‘cardioprotective’ ef-
fect.93,94 However, it has been shown that the
administration of b-adrenergic receptor antago-
nists in asthmatics can induce asthmatic attacks95
and increases the bronchoconstrictive response to
histamine and methacholine96 and clinical guide-
lines specify that b-adrenergic receptor antagonists
are contraindicated in asthma, even in the form of
topical eye-drops.3Cardiovascular influence of b-adrenoceptor
agonists in asthmatic patients
Garrard et al.62 noted that HR was significantly
higher for acute asthmatics than for either non-
asthmatic controls or asymptomatic asthmatics.
Several authors have since investigated the influ-
ence of b2-adrenoceptor agonists on HR and HRV
parameters in both the time and frequency
domains. Each of the main studies has reported
an increase in HR in medicated asthmatic subjects
compared with non-asthmatic and non-medicated
asthmatic controls following administration of
these drugs. Mean HR in non-asthmatics is signifi-
cantly increased following both salbutamol and
terbutaline.87,97,98 Interestingly, the relative in-
crease in HR following salbutamol in asthmatic
children is greater in the supine compared with the
standing posture.75 Furthermore, Hanratty et al.98
found that the time-domain parameters SDANN (an
LF analogue), RMSSD and PNN50 (HF analogues) and
SDNN (an index of Total HRV) were all significantly
reduced in healthy adults following the adminis-
tration of salbutamol compared with placebo.
Garrard et al.62 evaluated HR and frequency-
domain HRV parameters (LF, HF, LF/HF powers) in
asthmatic adults and normal controls. Subjects were
classified as either asymptomatic asthmatic or treated
asthmatic, the latter receiving a b2-adrenoceptor
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M.J. Lewis et al.1698agonist for acute asthma attacks. Control subjects
had significantly greater values of normalised LF
power than both asthmatic groups, the latter showing
no relative difference in this parameter. The control
group also displayed significantly higher values for the
LF/HF ratio than asymptomatic asthmatics, with no
significant differences between the other groups. In
contrast, Jartti et al. found that the LF/HF ratio was
significantly greater for both medicated asthmatic
children99 and adults97 compared with controls and
non-medicated asthmatics. In addition, Jartti et al.97
observed an increase in the LF component of adult
asthmatics following medication. A later study by
Eryonucu et al.87 investigated the specific effects of
salbutamol and terbutaline on HRV in adult asthmatic
patients. Changes in frequency-domain HRV para-
meters were similar following administration of the
two drugs and confirmed the data of Jartti et al.99 in
demonstrating a shift to sympathetic dominance: LF
and LF/HF ratio were significantly increased after
taking each drug. Jartti et al.75 also reported a
significant post-drug increase in the LF/HF ratio in
children, but observed a reduction in the LF
component in the standing posture. Only Jartti
et al. found any significant changes (reductions) in
the HF component of HRV after taking b2 agonist
medication in adults97 and children in the supine
posture.75 Garrard et al.,62 Jartti et al.75,97 and
Eryonucu et al.87 all observed significantly diminished
total HRV in asthmatics after taking these drugs.
Bremner et al.100 observed a tendency for both
hexoprenaline and salbutamol to increase systolic
BP and to reduce diastolic BP. However, Scheinin
et al.101 found no change in BP following salbuta-
mol and fenoterol, whilst Guhan et al.102 noted a
reduction in diastolic BP only following formoterol
and salmeterol. In addition to their work on HRV,
Jartti et al.99 also studied BP variability and BRS in
asthmatic and non-asthmatic children. Subjects
were assessed in both supine and standing postures
and during fixed and spontaneous breathing pat-
terns. It was found that HF (BP) was significantly
greater for non-medicated asthmatics compared
with non-asthmatics during all posture and breath-
ing conditions. The authors noted that this probably
indicated a mechanical respiratory (rather than a
vagal control) effect since there was no difference
in either HF (RR) or BRS between these groups. LF
(BP) during supine spontaneous breathing was
significantly greater in the medicated asthmatics
than in the other groups. The same researchers75
later found a tendency for a dose-dependant post-
drug reduction in BRS for children the standing
posture. In a subsequent study, Jartti et al.97
observed dose-dependant increases in LF (BP)
power, LF/HF (BP) ratio, and dose-dependantreductions in BRS following terbutaline administra-
tion in healthy adults. The clinical importance of
these specific changes is unknown. All variability
and BRS changes started to occur only after a
threshold terbutaline dose had been reached.
Jartti et al.78 investigated the influence on
cardiovascular autonomic regulation of a single
(acute) dose of a short-acting b2 agonist (salbuta-
mol) in asthmatic children who had taken a long-
acting b2 agonist (salmeterol) twice-daily for the
previous 4-week period. In agreement with their
previous work, these authors observed a shift to
sympathetic dominance in HRV and BPV following
regular salmeterol administration. Autonomic func-
tion tests performed pre- and 20min post-admin-
istration of the acute salbutamol dose showed that
4 weeks of salmeterol therapy diminished the acute
post-salbutamol changes in HR and HRV (shift to
sympathetic dominance) but did not affect the
bronchial dilation (PEFR) response. This indicated
that subjects had developed a slight tolerance to
the cardiovascular effects of salmeterol, whilst its
therapeutic effect was maintained.
Jartti et al.97 also examined the dose–response
effects of terbutaline on the complexity (approx-
imate entropy (ApEn) and fractal dimension (FD)) of
HR (RR interval) and systolic arterial BP (SAP)
signals in healthy adults. Dose-dependant reduc-
tions were observed in ApEn (RR), ApEn (SAP) and
FD (RR); reductions in FD (SAP) were not dose
dependant. Subsequently, Kuusela et al.103 used a
variety of non-linear data analysis techniques to
assess the effects of terbutaline on SAP and RR
signals in healthy adults. High doses of terbutaline
drastically reduced cardiac parasympathetic mod-
ulation and dampened arterial baroreceptor func-
tion. The mutual interaction of the BP and RR
systems was also weakened following terbutaline
administration, so that BP did not modulate HR
(i.e. there was no baroreceptor control) in this
condition. In fact it was determined that the
complexity (ApEn) of the RR signal was maintained
post-terbutaline but the BP signal became less
complex. Reduced cross-entropy showed that the
pattern architecture of the BP and RR signals
became more similar after terbutaline, the sug-
gested explanation for which was that, in this
state, respiration (an ‘external’ factor) modulates
both RR and BP signals.
It has been suggested that the positive chrono-
tropic, positive inotropic and systolic hyper-tensive
effects of b2-agonists leads to increased myocardial
oxygen consumption,104 and this might provoke
silent myocardial ischaemia or infarction. However,
no resultant myocardial ischaemia was observed by
Rossinen et al.105 in their study of the effects of
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co-existent with CAD. It should be noted that, in
disagreement with most other studies, these
authors also reported a lack of arrhythmias or
changes in HRV parameters for the same group of
subjects. Gaspardone et al.106 noted that intrave-
nous administration of salbutamol to patients with
CAD who were taking b-blocker medication dimin-
ished the time to onset of ischaemia and reduced
maximum exercise duration. Inhaled b2 agonist
(salbutamol) treatment has also been associated
with myocardial infarction107 and the b2 agonist has
occasionally caused myocardial injury when admi-
nistered by infusion during late pregnancy to
prevent preterm labour.108
Burggraaf et al.109 showed that patients with
asthma who were hypoxic and inhaled salbutamol
at a relatively low dose experienced significant and
potentially detrimental cardiovascular effects. In
that study salbutamol was administered 30min into
a 1-h period of mask breathing of ambient air or a
N2/O2 (hypoxic) mixture. Inhalation of salbutamol
during hypoxia resulted in a significant increase in
HR and peripheral blood flow (inversely propor-
tional to peripheral vascular resistance) at the end
of the assessment period, compared with salbuta-
mol inhalation during normoxia. The reported
positive chronotropic effect was in agreement with
previous reports of the effects of salbutamol during
hypoxaemia110 and during combined hypoxia
and hyper-capnia.111 In three of the 26 subjects
observed by Burggraaf et al.109 a rapid decline in
SpO2 (arterial oxyhemoglobin saturation measured
non-invasively by pulse oximetry) occurred follow-
ing salbutamol inhalation in the hypoxic state. This
was interpreted as an indication of pulmonary
shunting, the induction of which had previously
been associated with b2 agonists.
112 Burggraaf
et al.109 thereby provided a possible explanation
for the association between b2 agonist use and
sudden death in asthma: in the hypoxic state,
reduced peripheral resistance might decrease
venous return (especially when standing), eliciting
the Bezold–Jarisch reflex (hypoxic syncope) with
possible subsequent cardiac arrest.113
Salbutamol has been associated with hypokalae-
mia (an abnormally low concentration of potassium
ions in the blood) following intravenous, oral and
inhaled administration.79,111,114 Similar changes
have been observed after taking fenoterol,79
formoterol101 and salmeterol.101 Furthermore,
Jartti et al.97 suggested that the hypokalaemia
observed following terbutaline administration is
related to both arrhythmia and decreased HRV.
Scheinin et al.79 reported a reduction in the ECG T-
wave amplitude following salbutamol and fenoteroladministration in healthy subjects, but observed no
change in QRS duration despite an increase in HR
after taking these drugs. Bremner et al.100 found
that HR-corrected QT interval (QTc) tended to
increase following salbutamol. However, Burggraaf
et al.109 and Crane et al.77 found that salbutamol
had only a minor effect on QTc (o7% prolongation)
and serum potassium level (o5% decrease) during
both normoxia and hypoxia. It is therefore possible
that inhaled b2 agonist overdose might have
adverse clinical consequences in asthmatic patients
with pre-existing hypokalaemia. The risk of hypo-
kalaemia is higher when asthmatics take other
drugs e.g. steroids, thiazide or loop diuretics (for
hyper-tension) or if there are high circulating levels
of endogenous catecholamines (as might be caused
by the stress of a serious asthma attack). Patients
with concomitant heart disease or those using drugs
such as digitalis (which can sensitise the heart
to hypokalaemia) might also be at risk. Clinical
guidelines recommend monitoring serum potas-
sium, especially during emergency treatment.3
Formoterol is a full LABA and has an onset of action
within 6min with sustained action over 12–24 h; it
has now been licensed for top-up or as-required
inhalations, as part of a flexible dosing regime is
asthma. Any cardiovascular side effects may be
more problematical with repeated doses and a long
drug half-life.Influence of anticholinergic drugs
Cholinergic receptors in the airways and sinus node
are of the muscarinic type and can be blocked by
the anticholinergic drugs atropine115 and glycopyr-
rolate.116 Ipratropium bromide is an antimuscarinic
that can be used to provide short-term relief
(bronchodilation) in chronic asthma (although
short-acting b2 agonists work more quickly). When
taken in aerosol form, ipratropium bromide is
generally considered to act locally on the airways
of the lung without systemic effect117 and with no
significant effect on either cardiac vagal tone or
HR.118 Each of these cholinergic and muscarinic
receptor antagonists can substantially inhibit or
abolish the hyper-reactive response to inhaled
stimulants in asthmatics.19 Administration of atro-
pine or glycopyrrolate is the method of choice for
the assessment of tonic vagal activity.119,120 Aksel-
rod et al.121 first demonstrated pharmacological
parasympathetic blockade using power spectral
analysis of HR data following a single dose of
glycopyrrolate in dogs. This dose almost totally
abolished the HF peak of HRV, and the effect was
later confirmed in adults.122 Low doses of atropine
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fects on the heart, causing a decrease in HR18,123
and an increase in beat-to-beat HRV.124 Higher
doses of atropine cause an increase in HR and a
decrease in HRV.18,125 The HR reduction at low
doses of atropine is believed to be associated with
blockade of peripheral muscarinic M1 receptors at
sympathetic ganglia or inhibitory M1 receptors that
modulate acetylcholine release.126–128 The in-
creased HR at higher doses is likely to be caused
by the blocking of pre-synaptic M2 muscarinic
receptors.25 Parlow et al.116 have since detailed
the time course of parasympathetic blockade
following the administration of clinical doses of
common anticholinergic drugs, whilst Scheinin
et al.129 have developed a pharmacokinetic phar-
macodynamic (PK–PD) model for atropine and
glycopyrrolate using radioreceptor array (RRA)
and HRV methods.
Scheinin et al.129 examined the parasympatholy-
tic effects of atropine and glycopyrrolate with
regard to HRV in healthy non-asthmatics subjects.
These authors observed the following changes
(average values) in comparison with placebo
(physiological saline): 22% and 18% increases in
HR, respectively; 99% and 94% reductions in HF
power, respectively; decreased total and LF power
of HRV; 11- and 7-fold increases in the LF/HF ratio
of HRV; 87% and 73% reductions in the Hayano
index. Parlow et al.116 also compared the effects of
atropine and glycopyrrolate on HRV and BP in non-
asthmatic individuals. Mean cardiac (RR) interval
decreased significantly after both atropine and
glycopyrrolate, but systolic BP increased after
glycopyrrolate only. Atropine and glycopyrrolate
caused similar reductions in baroreceptor sensitiv-
ity (BRS), HF power and the HF/total power ratio.
The authors noted that atropine caused a signifi-
cantly greater duration of impaired cardiac para-
sympathetic control (of several hours duration,
measured using BRS and HRV) compared with
glycopyrrolate. Penttila et al.130 later demon-
strated that HF power and its time-domain analo-
gues (pNN50 and RMSSD) were almost completely
abolished in non-asthmatics following intravenous
glycopyrrolate infusion.
Horva´th et al.18 investigated the relationship
between bronchial and cardiac vagal tone in non-
atopic healthy adults. They examined the correla-
tion between changes in airway resistance and
changes in heart period in response to complete
pharmacologically induced cholinergic blockade
using atropine. The study assumed that the effects
of atropine on airway resistance (Raw) and RR
interval was entirely due to vagal blockade, there-
by allowing an assessment of vagal tone in eachsystem. The authors found that Raw (used as a
marker of bronchial vagal activity) and RR interval
(used as a marker of cardiac vagal activity)
decreased after full doses of atropine. However,
there was no correlation between the magnitude of
Raw and RR interval, suggesting a lack of association
between cardiac and bronchial vagal activity
(different central control). Morrison and Pearson70
found a strong correlation between the initial
responses of airway calibre and HR to vagal
blockade, although the bronchodilation effect
persisted longer than the cardioacceleration. The
authors suggested that this might be the result of
differing sensitivities of pulmonary and cardiac
muscarinic receptors to anticholinergic antagonists.
The newer, long-acting anticholinergic—tiotropium
bromide is currently not licensed for use in asthma.Discussion
There is an apparent association between altered
autonomic cardiovascular control and asthma. This
relationship is twofold: a consequence of both the
pathophysiology of asthma per se and the effects of
asthma pharmacotherapy. The full extent of these
changes, and their implications, have yet to be
fully quantified and their clinical significance may
have been overlooked. This autonomic and resul-
tant cardiac dysfunction may even contribute t
some sudden and often unexpected deaths in
patients with asthma.
Altered autonomic balance in the heart is clearly
associated with unfavourable prognosis in estab-
lished cardiovascular disease.131 Drugs that oppose
cardiac sympathetic stimulation (b-adrenoceptor
antagonists or ‘b-blockers’) improve patient survi-
val following myocardial infarction.132 b1 receptor
blockade in cardiovascular disease has been asso-
ciated with enhanced parasympathetic activity and
reduced sympathetic activity (assessed via HRV),
and this is generally accepted to confer a ‘cardi-
oprotective effect’.133 For example, the increased
LF/HF ratio in HRV that accompanies passive
orthostatic tilt is diminished after b-receptor
blockade.134 Conversely, several authors have
described a shift of HRV control towards sympa-
thetic dominance and reduced total HRV following
b2 agonist medication in asthma. A shift towards
sympathetic dominance in HRV has been associated
with mortality and morbidity, and specifically
with hyper-tension135 and an elevated risk of
sudden coronary death.136,137 It is therefore possi-
ble that bronchodilator therapy might be asso-
ciated with a detrimental change in the balance of
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borne in mind, however, that the relative impor-
tance of b1 and b2 adrenoceptors in the modulation
of autonomic control of the heart (HRV) is not
known at present,98 and this is certainly an area
worthy of further study. (It should be noted that the
administration of some b-adrenergic receptor
antagonists to asthmatics can induce asthma
attacks.138)
It would be useful to determine a reliable set of
baseline autonomic–cardiovascular indices for the
asthmatic condition. The rapid systemic changes
observed by Guhan et al.102 following inhalation of
both formoterol and salmeterol suggests that a
sizeable amount of drug is absorbed rapidly into the
blood. Peak plasma levels of formoterol, for
example, apparently occur within five minutes of
dose ventilation in normal subjects.139 Jartti
et al.75 noted that the main effects of salbutamol
on cardiovascular regulation had almost disap-
peared 2 h post-inhalation of the drug, although a
significant disturbance of sympathovagal balance
could still be identified at this time. Baseline
autonomic indices should therefore be defined with
regard to specified drug administration regimes.
Moreover, a physiological model should be devel-
oped that incorporates both acute and chronic
dynamic changes in these indices (that is, pertur-
bations owing to the effects of chronobiology,
antigen challenge or physical exercise). When
addressing these issues, future studies will need
to separately assess the pathophysiological and
pharmacological contributions to altered physiolo-
gical function in the asthmatic individual.
The early study of Kaliner et al.4 demonstrated
that both asthmatic and allergic (atopic) indivi-
duals are hypo-reactive to b-adrenergic stimuli and
hyper-reactive to cholinergic stimuli. In order to
determine the origin of these altered sensitivities,
investigations should include a comparison of
atopic and non-atopic individuals (asthmatics and
non-asthmatics). In particular it would be of great
clinical value to quantify the autonomic-cardiovas-
cular indices for each of these subject groups.
b agonists are classified by adrenoceptor selec-
tivity, potency and pharmacological efficiency. All
currently available synthetic b2 agonist bronchodi-
lators are ‘good’ to ‘highly selective’ agonists at
the b2 receptor (the exception is isoproterenol
(isoprenaline) which is approximately equally ac-
tive on b1 and b2 receptors). The majority of these
are also ‘partial agonists’ in that they activate
signal transduction at the receptor less efficiently
and to a lesser extent than the natural catechola-
mine adrenaline. (For further details on b adreno-
ceptor agonist drugs see Lipworth and Grove.140)Despite their apparently similar properties, it
would be useful to compare the specific auto-
nomic-cardiovascular influences of each of the
main bronchodilators and combination therapies.
Bennett et al.141 observed that the majority (of the
order two-thirds) of systemic effects of salmeterol
inhaled via a metered dose inhaler were the result
of drug absorption from the lung, with the remain-
ing one-third from gastrointestinal absorption.
Comparison of the relative autonomic-cardiovascu-
lar influence of primary routes of absorption for
different drugs would be another interesting
challenge.
An appropriate standard methodology for the
assessment of cardiovascular and respiratory auto-
nomic function now needs to be developed. This is
likely to involve the non-invasive, synchronised
quantification of HR and BP variabilities, BRS and
other beat-to-beat haemodynamic parameters.
A patient assessment protocol that involves paced
and spontaneous breathing (when clinically
stable), standardised static and dynamic exercise,
or multiple postural-shift phases, will facilitate
provocation of state changes in the autonomic,
cardiovascular and haemodynamic systems. This
will facilitate computational modelling of both
normal cardiovascular–respiratory ANS activity in
asthma and it’s treatment. The development of
advanced power spectral and non-linear analysis
techniques, as described by Jartti et al.97 and
Kuusela et al.103 are likely to be instrumental in this
goal.
It is now timely and technologically feasible to
elucidate specific ANS changes in asthma and,
importantly, to determine the clinical implications
of these changes. Autonomic-cardiovascular inves-
tigation should be a priority focus in future asthma
research.
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